Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 01, 2023

BUY
$10.78 - $17.73 $271,267 - $446,157
25,164 Added 0.34%
7,532,841 $90.4 Billion
Q1 2023

May 11, 2023

SELL
$13.02 - $19.87 $82,416 - $125,777
-6,330 Reduced 0.08%
7,507,677 $97.7 Million
Q4 2022

Jan 27, 2023

SELL
$7.65 - $15.51 $8.14 Million - $16.5 Million
-1,063,430 Reduced 12.4%
7,514,007 $0
Q3 2022

Nov 01, 2022

BUY
$8.63 - $15.52 $13.8 Million - $24.8 Million
1,600,209 Added 22.93%
8,577,437 $77.2 Million
Q2 2022

Aug 25, 2022

BUY
$8.59 - $20.77 $10.9 Million - $26.4 Million
1,272,331 Added 22.3%
6,977,228 $90.7 Million
Q1 2022

May 13, 2022

BUY
$15.52 - $35.65 $25.3 Million - $58.2 Million
1,632,967 Added 40.1%
5,704,897 $108 Million
Q4 2021

Jan 18, 2022

SELL
$28.89 - $35.33 $8.84 Million - $10.8 Million
-305,872 Reduced 6.99%
4,071,930 $143 Million
Q3 2021

Nov 09, 2021

SELL
$35.66 - $42.94 $4.81 Million - $5.79 Million
-134,760 Reduced 2.99%
4,377,802 $160 Million
Q2 2021

Aug 16, 2021

BUY
$23.7 - $39.27 $33.9 Million - $56.1 Million
1,428,962 Added 46.34%
4,512,562 $176 Million
Q1 2021

May 12, 2021

SELL
$27.01 - $36.8 $344,242 - $469,015
-12,745 Reduced 0.41%
3,083,600 $86.3 Million
Q4 2020

Feb 02, 2021

SELL
$27.51 - $34.36 $8.38 Million - $10.5 Million
-304,471 Reduced 8.95%
3,096,345 $99.1 Million
Q3 2020

Oct 26, 2020

SELL
$25.8 - $34.61 $1.6 Million - $2.15 Million
-62,059 Reduced 1.79%
3,400,816 $109 Million
Q2 2020

Jul 22, 2020

SELL
$17.65 - $28.05 $7.72 Million - $12.3 Million
-437,314 Reduced 11.21%
3,462,875 $97 Million
Q1 2020

Apr 09, 2020

BUY
$15.19 - $29.51 $1.02 Million - $1.98 Million
67,134 Added 1.75%
3,900,189 $70.2 Million
Q4 2019

Jan 28, 2020

BUY
$17.17 - $25.95 $65.8 Million - $99.5 Million
3,833,055 New
3,833,055 $95.8 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track M&G Investment Management LTD Portfolio

Follow M&G Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&G Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on M&G Investment Management LTD with notifications on news.